Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy

Abstract excerpt

Myasthenia gravis (MG) is an autoantibody-mediated autoimmune disorder of the neuromuscular junction. A small subset of patients (<10%) with MG, have autoantibodies targeting muscle-specific tyrosine kinase (MuSK). MuSK MG patients respond well to CD20-mediated B cell depletion therapy (BCDT); most achieve complete stable remission. However, relapse often occurs. To further understand the immunomechanisms...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Treatment and Pharmacology
• Share to Myasthenia Gravis and Thymoma
• Share to Peripheral Neuropathies and Disorders